Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …

Background The discovery of somatostatin (SST) and the synthesis of a variety of analogues
constituted a major therapeutic advance in the treatment of gastroenteropancreatic …

Since highly proliferative carcinomas with a neuroendocrine phenotype but poor histological
differentiation grade are extremely rare in the jejuno-ileum, management of such cases …

111In-diethylenetriaminepentaacetic acid (DTPA)-octreotide scintigraphy is currently the
nuclear medicine imaging modality of choice for identifying neuroendocrine tumors …

Functional techniques are playing a pivotal role in the imaging of cancer today. Our aim was
to compare, on a head-to-head basis, 3 functional imaging techniques in patients with …

Abstract The 2019 World Health Organization (WHO) classification of gastrointestinal tumors
defines well‑differentiated grade 3 neuroendocrine tumors, the mixed neuroendocrine‑non …

The incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-
NETs) have increased in the past 20 years. GEP-NETs are heterogeneous tumors, in terms …

Simple Summary Peptide receptor radionuclide therapy (PRRT) is one of the treatment
options for locally advanced or metastatic gastroenteropancreatic (GEP) neuroendocrine …

Objective Somatostatin receptors (SSTRs), products of gene superfamily SSTR1-5, are
commonly expressed in neuroendocrine tumors (NETs). Somatostatin analogs (SSAs) bind …

To date, empirical literature has generally been considered lacking in relation to
neuroendocrine carcinomas (NECs), the highly malignant subgroup of neuroendocrine …